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1. Introduction 
Throughout history, humanity has referred to toxic reactions in response to food, plants, and 
more recently, medications or drugs. Pythagoras is thought to be one of the first to observe 
that some individuals, but not all, would get sick after eating fava beans. Introduction of the 
complex term pharmakon (a word used to designate substances that may produce beneficial or 
harmful effects to human health) by Hippocratic physicians brought with it a paradox: a 
compound may be served both as a drug and a poison at the same time. As it is currently 
known, administration of a substance may offer higher risk of toxic effects than when 
administered at a lower dose. But then, what about a drug dosage that induces toxicity in a 
patient, treats another well and had no effects on the other? This and other important 
observations such as the understanding of metabolic variability  have started to unravel the 
mysteries behind these phenomena. For example, the ancient observation why different 
outcomes were regularly observed after Greek soldiers ate fresh fava beans (Nebert 1999). 
The concept of ‘variability in metabolism’ claims that biochemical processes within the 
organism are responsible for transformation of compounds from food or medicines, and that 
this process could be different among subjects leading to a range of organic responses. 
Alexander Ure (1841) seems to have been the first to report organism’s ability to convert an 
exogenously administered compound into one or more different metabolites. In the study 
entitled ‘On Gouty Concretions with a New Method of Treatment', Ure reported that benzoic 
acid was converted to hippuric acid by humans (Ure 1841). Then, it gradually began to be 
accepted that living systems have a “physiological chemistry” responsible for the 
modification of substances, and from the second part of 19th century, a significant number of 
metabolic pathways have been discovered.  
At that time, however, the key answer to why there is individual variability in metabolism had 
not yet been answered, which only came to light after the rediscovery of Mendel´s study about 
hereditary around the turn of the 20th century. A well-known example to illustrate this was the 
influence of the genetic findings of William Bateson on studies of Sir Archibald Garrod about 
alkaptonuria and phenylketonuria presented in the book entitled “Inborn Errors of Metabolism” 
(Garrod 1909). In fact, the results founded by Garrod were a milestone to explanation of 
metabolic variability from a genetic perspective. Thereafter, some forerunners separately 
described series of observations that preceded the conceptualization of the Pharmacogenetics 
(PGx). In 1932, Arthur Fox found a remarkable variation in the ability of some individuals to 
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taste a foreign chemical phenylthiocarbamide (PTC) (the ‘taste blindness’) (Fox 1932). 
Interestingly, this finding was unexpectedly discovered when some of the PTC molecules 
escaped in to the air and Fox’s co-worker C.R. Noller noticed a bitter taste, while Fox could not 
taste it. Intrigued by Fox’s findings about bitter taste, L.H. Snyder published an important 
study (especially for the relevant quantity of participants) confirming the Fox’s observation 
that some people perceive the bitter taste of PTC, while others do not. In addition, Snyder 
found that such non-tasting is a recessive genetic trait, and today it is one of the best-known 
Mendelian traits in human populations (Snyder 1932).  
 In a similar fashion, animal studies at that time also supported the genetic contribution in 
drug metabolism variability. Sawin and Glick (1943) in the study entitled “Atropinesterase, a 
Genetically Determined Enzyme in the Rabbit” demonstrated a genetically determined outcome 
in rabbits after ingestion of the belladonna leaves (Sawin & Glick 1943). 
In the middle of 20th century, evidences necessary to support the transformation of the 
scattered “pharmacological heritability” in a new science finally appeared. First, Hettie 
Hughes described a relation between the level of isoniazid (an anti-tuberculosis drug) 
acetylation and occurrence of peripheral neuritis (Hughes et al. 1954), which absolutely was 
a landmark step for future demystification of the "one size fits all" system of drug 
prescribing. Another milestone in PGx was an independent investigation about death of 
patients caused by a generally safe, local anesthetic drug procaine (Kalow 1962). Further 
experiments enabled the authors to suggest that a genetically determined alteration in the 
enzyme structure may cause an abnormal and lethal low cholinesterase activity. The atypical 
enzyme does not hydrolyze the anesthetic with efficacy, resulting in a prolonged period of 
high levels of the drug in the blood and increased toxicity (Kalow 2005). Simultaneously, Alf 
Alving and co-workers observed that African-American soldiers presented an increased risk to 
develop acute haemolytic crises after primaquine (an antimalarial drug) administration, when 
compared with Caucasian ones (Clayman et al. 1952).  As shown later, this sensitivity is caused 
by a genetically determined deficiency of glucose 6-phosphate dehydrogenase (G6PD), which 
alters erythrocyte metabolism (Alving et al. 1956). Thus, it took approximately 2,400 years to 
explain the Pythagoras observation about favism from a molecular perspective. It is now 
believed that defect in the G6PD gene is related with fava-induced hemolytic anemia in some 
individuals of Mediterranean descent.  
Finally, opening a new era of pharmacological investigation, Arno Motulsky in 1957 published 
a masterpiece paper entitled “Drug reactions, enzymes and biochemical genetics”, highlighting the 
genetic basis of “how hereditary gene-controlled enzymatic factors determine why, with 
identical exposure, certain individuals become ‘sick’, whereas others are not affected” 
(Motulsky 1957).  The works of Kalow and Motulsky were (and still are) an unequivocal 
scientific catalyzer for understanding of the genetic influence in drug metabolism. Friedrich 
Vogel, a German Pharmacologist in 1959 was the first to coin the term ‘Pharmacogenetics’ 
(PGx) for the emergent new area of scientific discoveries, that unifies different conceptions on 
pharmacotherapy and xenobiotic-induced disease risk (Vogel 1959).  
Despite the terms Pharmacogenetics and Pharmacogenomics are used interchangeably, most 
authors prefer to use PGx when inherited differences in drug response are being evaluated. 
On the other hand, Pharmacogenomics is usually used to study general aspects of drug 
response involving genomic technologies to determine a drug profile or even a new drug.  
Although is common association between PGx and drug metabolism variation, many others 
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inherited differences in drug response are investigated by PGx, such as polymorphisms in 
genes that encode molecules transporters (Vaalburg et al. 2005) and drug targets (Johnson & 
Liggett 2011; Maggo et al. 2011). For practical purposes, preference will be given to the use 
of the term Pharmacogenetics throughout this chapter. 
2. Metabolizers subpopulations, a brief review 
Since physiological responses associated with a particular drug have been linked to 
biochemical attributes in the body of the recipient, several studies have attempted to elucidate 
which factors modify the clinical response to a greater or lesser extent. There is now a general 
understanding that variability in the function of drug-metabolizing enzymes (DME) is 
responsible for many differences in the disposition and clinical consequences of drugs. 
Although it is a central issue to PGx, in clinical practice most decisions about a medicine 
prescription are mainly based on the classic factors responsible for drug variability, including 
co-existing disease (especially those that affect drug distribution, absorption or elimination), 
body mass, diet, alcohol intake, interaction with others drugs and mechanisms to improve 
patient compliance. In fact, all of these have been demonstrated to directly affect the indicated 
dose of the drug. However, they only partly explain why most major drugs are effective in 
only 25 to 60 percent of patients. Furthermore, taking into account patients with same physical 
and demographic characteristics, why does a standard dose is toxic to some patient but not to 
others? Why not all patients demonstrate the expected efficacy in drug treatment trials? 
Undoubtedly, these and many others questions opened the door for a new era of the 
personalized medicine and treatment perspectives (Nair 2010).   
It is well-know that drug levels can be raised by increasing the dose or by more frequent 
administration in a non-responder patient. Conversely, if a higher plasmatic drug level with a 
standard dose administration is expected (in a patient with cirrhosis or malnutrition, for 
example), increasing the time of administration or suspending the dose may be a reasonable 
attitude. Although advances in medical technology and potential predictive models have 
improved the choice of dose, they are not yet sufficient to prevent high level of morbidity and 
mortality caused by adverse drug reactions (ADR), as shown in the clinical practice (Wu et al. 
2010). Thus, it is believed that the study of how genetic variation interface with drug 
metabolism, especially in genes codifying DMEs, may also lead to improve drug safety. 
A variety of factors affecting the expression and activity of DMEs are classified into three 
major groups: genetic factors, non-genetic host factors (such as diseases, age, stress, 
obesity, physical exercise, etc.) and environmental factors (environmental pollutants, 
occupational chemicals, drugs, etc.). Recent studies clearly indicate that interindividual 
variation in drug metabolism is one of the most important causes of drug response 
differences.  In general, common pharmacokinetic profile is a lighthouse for most 
prescribers in clinical practice. Figure 1A exemplify a simplified model of a drug 
biotransformation route. Most pharmaceuticals compounds or molecules (M1 in figure 1) 
when administrated orally are lipid-soluble enough to be reabsorbed (in the kidneys) and 
eliminated slowly in small amounts in an unchanged form in urine. Therefore, drug 
biotransformation by enzymes (represented by E1) has a key role in the control of plasmatic 
drug concentration. It should be remembered that the metabolites (M2) might also exert 
pharmacological effect (which will be discussed later). In addition, low activity of the  
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Fig. 1. Overview of the expected clinical result and its relation with activity of drug 
metabolizing enzymes. M1: pharmaceuticals compounds; E1: phase I biotransformation;  
M2 and M3: metabolites; E2: phase II biotransformation 
metabolic step might cause accumulation of the drug and/or its metabolites in the body if 
the medicine continues to be taken (Figure 1B). As discussed earlier, genetic mutations in 
coding and noncoding regions may be involved in such inborn altered enzymatic activity 
(Ingelman-Sundberg 2001). Some relevant examples come from polymorphisms in CYPs 
(cytochrome P450) genes, which may result in absence of protein synthesis (2A6*4, 2D6*5), 
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no enzyme activity (2A6*2, 2C19*2, 2C19*3, 2D6*4), altered substrate specificity (2C9*3), 
reduced affinity for substrate (2D6*17, 3A4*2), decreased stability (2D6*10) or even increased 
enzyme activity (2D6*2xn) (Tang et al. 2005). It is important to note that such genetically 
determined enzyme variation may directly interfere in the drug concentration at the target 
tissue, and though the pharmacological effect may be observed, the risk of toxicity will also 
be higher in “poor metabolizers” since it might accumulate to possibly harmful levels. 
Reduction in drug biotransformation, as observed in drug-drug interactions, will also result 
in altered expected values for the constant of elimination (Ke), half-life of the drug (t½), 
volume of distribution (Vd), area under the curve (AUC) and others common useful 
pharmacokinetic parameters used in therapeutic drug monitoring and adjustment. Based on 
these reasons, PGx approaches may contribute to the enhancement of clinical outcomes by 
providing a more effective match between patient and drug dose or type, and consequently 
reducing the probability of an adverse drug reaction. 
Since the effect of inherited variation (genotype) on enzymatic activity isresult of changes in 
DNA sequence (will be discussed in more details later), it is plausible that there are distinct 
subgroups of subjects who have different metabolic capabilities (phenotype). IIndeed, 
epidemiologic studies have revealed at least two sub-populations of individuals based on 
drug metabolizing profile, classified as either “rapid”, or “slow” metabolizers. Importantly 
to note that each metabolic group (rapid or slow) has advantages and disadvantages, and 
potential outcomes have been related to the type of drug studied. For example, 
administration of a prodrug may have higher therapeutic efficacy in a rapid than in slow 
metabolizer phenotype, as the metabolization of such drug is necessary to make it active. In 
addition, drug biotransformation is fundamental to generate an active-molecule (M2) from a 
less (or not) active form (M1) (Figure 1C). Despite controversies that exist in the literature 
about the real impact of pharmacogenetics on clinical practice (Padol et al. 2006), studies 
have reported different therapeutic response in patients treated with proton pump 
inhibitors (Tanigawara et al. 1999; Furuta et al. 2001; Klotz 2006). These examples illustrate 
how important PGx is, on a case-by-case basis. 
Furthermore, it is evident that PGx approaches cited here are simplified assumptions of 
metabolism. Actually, many drugs are sequentially metabolized (Figure 1D) by parallel 
pathways or a broad range of enzymes to other intermediary metabolites. For practical 
purposes, two main classes of reactions are considered in the biotransformation of drugs. 
Exclusively for readability, some basic generalities of each phase reactions will be 
introduced below from a PGx perspective. 
3. Lessons from phase I and II reactions  
As discussed elsewhere in this book, the “phase I” metabolizing enzymes (or “nonsynthetic 
reactions”) can convert drugs in reactive electrophilic metabolites by oxidation, hydrolysis, 
cyclization, reduction, and decyclization. The major and the most common phase I enzyme 
involved in drug metabolism are the microsomal cytochrome P450 (CYP) superfamily. CYPs 
mediate monooxygenase reactions that generate polar metabolites that may be readily 
excreted in the urine. Major CYP isoforms responsible for biotransformation of drugs 
include CYP3A4, CYP2D6, CYP2C9, CYP2C19, CYP1A2 and CYP2E1. However, CYP2D6, a 
member of this family, has been a true landmark in phase I reactions and also a common 
target of study in PGx.  
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Following the scientific vision of Evans and Sjöqvist concerning the inheritability of 
metabolism profile, Alexanderson continued the refining of the pharmacogenetic studies 
using twin models. Metabolism of some drugs such as nortriptiline (tricyclic antidepressant) 
were demonstrated to be under genetic control (Alexanderson et al. 1969). Later, Robert 
Smith (Mahgoub et al. 1977) and Michel Eichelbaum (Eichelbaum et al. 1979) and their co-
workers independently attributed variability in debrisoquine/sparteine oxidation to feasible 
genetic polymorphisms in debrisoquine hydroxylase or sparteine oxidase (now known as 
CIP2D6, the same metabolizing enzyme of nortriptiline). In these studies, they suggested 
that at least two phenotypic subpopulations could be distinguished as “poor” and 
“extensive” metabolizers. This association between genotype and phenotype was explored 
only almost ten years after, when the gene encoding CYP2D6 was identified  (Gonzalez et al. 
1988). Nowadays, it is well recognized that CYP2D6 polymorphisms may result in four 
phenotypes according to enzyme activity: poor metabolizers (PMs); intermediate 
metabolizers (IMs); extensive metabolizers (EMs); and ultrarapid metabolizers (UMs). The 
EM phenotype, considered as “reference”, is the most frequent in worldwide populations. 
PMs inherit two deficient CYP2D6 alleles, which result in a significant slower CYP2D6 
metabolism rate (characterized by increase of the plasma drug levels) (Figure 2). Individuals 
carrying only one defective CYP2D6 allele are considered IMs, the “functional” phenotype. 
Since IMs still have some CYP2D6 metabolic activity, pharmacological responses in those 
patients are considered marginally better than those observed in PM phenotype.  
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Fig. 2. Effect of functional CYP2D6 genes in mean plasma concentrations of nortriptyline 
after a 25-mg oral dose administration. (Dalen et al. 1998). 
The UM phenotype results from a gene duplication or even multiduplications. Individuals 
UMs tend to metabolize drugs at an ultrarapid rate (Ingelman-Sundberg et al. 2007). The 
relevance of such genetic variation in the biotransformation of drugs is very impressive. 
First, at least one fifth of all drugs used in clinical practice (or their active metabolites) share 
a pathway in CYP2D6 route. Among them, include those used to treat heart disease, 
depression and schizophrenia, for example (Ingelman-Sundberg & Sim 2010; Lohoff & 
Ferraro 2010). Second, phenotype status directly affects clinical response. Analgesic effects 
of some prodrugs, such as tramadol, codeine and oxycodone are CYP2D6-dependent, and 
PMs present low analgesic efficacy (Poulsen et al. 1996; Stamer et al. 2003; Stamer & Stuber 
2007; Zwisler et al. 2009).   On the other hand, loss of therapeutic efficacy at standard doses 
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can also be observed in UMs since the drug metabolization occurs at a fast rate (Davis & 
Homsi 2001). Finally, UM may also present either improved therapeutic efficacy or more 
frequently severe adverse effects, due to a higher rate of toxic metabolites formation 
(Kirchheiner et al. 2008; Elkalioubie et al. 2011).  
An interesting point is that many chemicals become more toxic (even carcinogenic) only 
when they are converted to a reactive form by phase 1 enzyme (represented by M2 in Figure 
1D). Thus, subsequent biotransformation pathway has a critical role in protecting cells from 
damage by promoting elimination of such potentially dangerous compounds. In this 
context, many phase I products are not rapidly eliminated and they may undergo a 
subsequent reaction, known as phase II (represented by E2 in Figure 1D). Phase II reactions 
are characterized by incorporation of an endogenous substrate (for this reason are called 
“conjugation reactions”) such as glutathione (GSH), sulfate, glycine, or glucuronic acid 
within specific sites in the target containing mainly carboxyl (-COOH), hydroxyl (-OH), 
amino (-NH2), and sulfhydryl (-SH) groups to form a highly polar conjugate (represented by 
M3 in the figure 1D). As phase I, most phase II reactions generally produces more water-
soluble metabolites, increasing the rate of their excretion from the body. However, it is 
important to notice that the conjugation of reactive compounds by phase 2 metabolizing 
enzymes will not necessarily convert them into inactive compounds before elimination. 
Actually, “phase I” and “phase II” terminologies have been more related to a historical 
classification rather than a biologically based one, since phase II reactions can occur alone, or 
even precede phase I reactions. In general, more complex routes are involved in drug 
metabolism though some pathways are preferentially used.  
It is worthwhile to mention some clinical considerations with regard to recent advances seen 
in PGx. First, although genotyping may be useful in predicting a drug response or 
toxicological risk, classical factors related with variability in drug response (age, organic 
status, patient compliance and others) must also be considered at every stage of the 
therapeutic individualization (Vetti et al. 2010). Second, it is widely accepted that genetic 
variability in DMEs are also directly correlated with susceptibility to unexpected outcomes, 
such as suicide (Penas-Lledo et al. 2011), cancer (Di Pietro et al. 2010) and other complex 
diseases (Ma et al. 2011). In others words, PGx approaches are not limited to drug response.  
Knowledge of the relevance of phase II enzymes for PGx precedes the CYP2D6 findings. The 
final touch of this association was done by Price Evans in an elegant and well-designed 
research on the Finish in 1950`s (Evans et al. 1960). Although his studies about variation of 
isoniazid metabolism had more impact on public health, Evans advanced the ideas of 
Hughes and McCusick about the influence of Mendelian inheritance on drug metabolism. In 
this regard, his findings allowed introduction of the ‘fast' and ‘slow' metabolizers 
nomenclature, and which finally provided evidences that genetic variation in drug 
metabolism could be shown using random families. Subsequent studies demonstrated that 
the common trimodal profile in plasma isoniazid levels as a result of genetically determined 
forms of hepatic N-acetyltransferase (NAT). Particularly NAT2 (EC 2.3.1.5), catalyzes not 
only N-acetylation, but following N-hydroxylation also catalyzes subsequent O-acetylation 
and N,O-acetylation. NAT2 is a crucial enzyme to convert some environmental carcinogens 
such as polycyclic aromatic hydrocarbons (PAHs), aromatic amines (AAs), heterocyclic 
amines (HAs) and nitrosamines (NAs) in more water-soluble metabolite, avoiding 
accumulation of potentially dangerous metabolites (Hein et al. 2000). 
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Fig. 3. Polymodal distribution of plasmatic concentrations after an oral dose of isoniazid in 
267 subjects  (Price-Evans 1962).  
Other important phase II enzymes are Glutathione S-transferases (GSTs; EC 2.5.1.18), 
which constitute a superfamily of ubiquitous and multifunctional enzymes. As NAT2, GSTs 
play a key role in cellular detoxification, protecting macromolecules from attack by reactive 
electrophiles, including environmental carcinogens, reactive oxygen species and 
chemotherapeutic agents (Ginsberg et al. 2009). One common feature of all GSTs is their 
ability to catalyze the nucleophilic addition of the tripeptide glutathione (GSH; γ-Glu-Cys-
Gly) to a wide variety of exogenous and endogenous chemicals with electrophilic functional 
groups, thereby neutralizing such sites, and similar with NAT2, rendering the products 
more water-soluble, facilitating their elimination from the cell. Besides NATs and GSTs, 
other enzymes are also important in phase II metabolism, such as UDP-glucuronosyl 
transferases (UGTs), sulfotransferases (SULTs), methyltransferases (as TPMT) and 
acyltransferases (as GNPAT).  
Assumptions between functional variability in DMEs and heritable genetic polymorphisms 
have allowed recent studies to evaluate, for example, why exposition to a particular toxic 
substance does not result in the same degree of risk for all individuals. This approach called 
toxicogenetics is considered another arm of PGx. Additionally, toxicological perspectives 
provide opportunities to evaluate the interindividual variability in susceptibility to a 
number of disorders such as cancer (Orphanides & Kimber 2003; Di Pietro et al. 2010).  As 
discussed later, it is inevitable that this knowledge would bring out endless debates about 
ethical questions. 
4. Genetic variability in drug response 
At this point, it is clear that variability in drug response depends on the complex interplay 
between multiple factors (including age, organ function, concomitant therapy, drug 
interactions, and the nature of the disease) and genetic background. Now, we will focus on 
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the basic principles of genetics to get a better understanding of key issues addressed in PGx, 
and how genotype data may be used to infer phenotypic designations.  
DNA sequence variations that are common in the population (present at frequencies of 1% 
or higher) are known as polymorphisms (not just “mutations”) and they influence the 
function of their encoded protein, consequently altering human phenotypes. Among such 
genetic variations, there are at least two common polymorphisms having a substantial 
influence on the interindividual variation in human metabolism: Single Nucleotide 
Polymorphisms (SNPs) and insertions/deletions (indels). SNPs are polymorphisms that 
occur when a single nucleotide (A, T, C, or G) is altered in the genome sequence. They are 
largely distributed and account for most variations found in the genome. However, those 
that occur in genes and surrounding regions of the genome controlling gene expression are 
notoriously related to susceptibility to diseases or have a direct effect on drug metabolism.  
SNPs are classified as nonsynonymous (or missense) if the base pair change results in an 
amino acid substitution, or synonymous (or sense) if the base pair substitution within a 
codon does not alter the encoded amino acid. In comparison to base pair substitutions, 
indels are much less frequent in the genome, especially in coding regions. Most indels 
within exons (representative nucleotide sequences that code for mature RNA), may cause a 
frame shift in the translated protein and thereby changing protein structure or function, or 
result in an early stop codon, which makes an unstable or nonfunctional protein. Important 
to state that the functional effects of structural genomic variants are not limited by SNPs and 
indels, but also related to others process such as inversion and multiple copies of genes (as 
observed in CYP2D6), and even the occurrence of a new gene-fusion products. 
As presented earlier, population studies have shown the frequency of an appropriate 
measure of in vivo enzyme activity frequently bimodal (with two phenotypes generally 
termed rapid and slow metabolizers). However, as observed in CYP2D6 gene, additional 
phenotypes such as the ultrarapid (those with markedly enhanced activity) or intermediate 
metabolizers can be detected, resulting in subsets of individuals who differ from the 
majority (polymodal). As this phenotypic distribution is determined by genetic 
polymorphisms, the knowledge of alleles variants in selected genes may provide a basis for 
understanding and predicting individual differences in drug response. Here, we selected the 
NAT2 gene, a clinically relevant gene example, to illustrate how PGx data may provide 
molecular diagnostic methods to improve drug therapy. 
4.1 NAT2: Genetic determinants to a range of phenotypes 
The gene coding for NAT2 is located within 170 kb mapped to the short arm of human 
chromosome 8p22. NAT2 codifies a 290 amino acid product from the intronless 870 base pair 
open reading frame (Blum et al. 1990). Numerous allelic variants have been described for 
NAT2. Although the SNPs in the coding exon causing amino acid changes remain most 
investigated, recent studies have described some NAT2 SNPs that do not change amino acid 
codon but may have functional consequences in transcript stability and splicing. NAT2 
SNPs are described in detail on the website http://louisville.edu/medschool 
/pharmacology/consensus-human-arylamine-n-acetyltransferase-gene-nomenclature).  
A number of studies have attempted to relate NAT2 SNPs to interindividual differences in 
response to drugs or in disease susceptibility, however some inconsistencies were observed. 
www.intechopen.com
 
Topics on Drug Metabolism 
 
70
A reasonable explanation for this contradictions is that genotyping of individuals SNPs 
alone may not always provide enough information to reach these goals at genes containing 
multiple SNPs in high linkage disequilibrium such as NAT2 (Sabbagh & Darlu 2005). 
Therefore, it seems more desirable that various combinations of NAT2 SNPs, known as 
haplotypes, rather than individual SNPs can be required to infer phenotypes of NAT2 
acetylation in a trimodal distribution of rapid, intermediate and slow (Vatsis et al. 1995). 
Thus, genetic alterations in NAT2 described so far stem primarily from various haplotypes 
of 20 nonsynonymous (C29T, G152T, G191A, T341C, G364A, C403G, A411T, A434C, A472C, 
G499A, A518G, C578T, G590A, G609T, T622C, C638T, A803G, G838A, A845C, and G857A) and 
seven synonymous SNPs (T111C, C228T, C282T, C345T, C481T, A600G and C759T) in the 
NAT2 coding exon.  
Metabolic phenotyping assays are generally more time-consuming, more expensive, and not 
suitable in many situations. In this regard, many studies have successfully shown that 
phenotype prediction of NAT2 activity from genotype data is useful and accurate. However, 
this requires that all relevant SNPs and/or alleles be analyzed in the population studied 
since inference of NAT2 phenotypes is assigned based on co-dominant expression of rapid 
and slow acetylator NAT2 SNPs, as previously shown (Xu et al. 2002). For example, 
individuals that have one or more slow acetylator NAT2 SNPs such as A191G, T341C, G590A 
or G857A are deduced as slow acetylators since these substitutions are diagnostic for 
defective NAT2 function. However, if at least one rapid NAT2 SNP is also present, an 
intermediate acetylator is observed. Failure to detect this hypothetical rapid SNP may 
explain, in part, an unreliable enzymatic prediction or even unexpected clinical outcomes. 
On the other hand, there is still no consensus about the number of NAT2 SNPs considered 
necessary to infer accurately the human acetylator status. Many studies have performed 
genotyping using 4 SNPs (A191G, C341T, A590G and A857G), but some authors 
demonstrated that analysis at least of seven SNPs (adding C282T, C481T and A803G) seems 
more accurate to infer the NAT2 acetylator phenotypes (Deitz et al. 2004). It is important to 
note that this accuracy may vary depending on the ancestral background of the population 
under study because the SNP prevalence differs among ethnic groups. For example, our 
research group found that G590A, common to the NAT2*6 slow haplotype, is present in 
almost all Afro-Brazilians and Caucasians, but present only in half of Amerindians (Talbot 
et al. 2010). In fact, even the reference haplotype considered “wild-type” is not common in 
all ethnic groups. The most common and clinically relevant NAT2 haplotypes that have been 
the subject of most studies in recent years are illustrated in Table 1. 
4.2 Why computational approach is valuable to infer haplotypes? 
Haplotype approaches combining the information of adjacent SNPs into composite 
multilocus are more informative, robust and valuable in the study of human traits than 
single-locus analyses. However, problems may occur when NAT2 SNPs are assigned to a 
particular combination of two multilocus haplotypes because most NAT2 SNPs are found 
in high linkage disequilibrium and haplotype assembly from available genotype data 
which may a challenging task. In other words, the gametic phase of haplotypes  
is inherently ambiguous when individuals are heterozygous at more than one locus 
(Figure 4). 
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Haplotype 
SNP and 
rs identifiers 
Amino-acid 
change 
Acetylator 
phenotype 
    
NAT2*4 Reference Reference High 
    
NAT2*5A 
T341C (rs1801280) 
C481T (rs1799929) 
I114T 
L161L 
Slow 
    
NAT2*5B 
T341C (rs1801280) 
C481T (rs1799929) 
A803G (rs1208) 
I114T 
L161L 
K268R 
Slow 
    
NAT2*5C 
T341C (rs1801280) 
A803G (rs1208)
I114T 
K268R
Slow 
    
NAT2*6A 
C282T (rs1041983) 
G590A (rs1799930) 
Y94Y 
R197Q 
Slow 
    
NAT2*6B G590A (rs1799930) R197Q Slow 
    
NAT2*7A G857A (rs1799931) G286E Slow* 
    
NAT2*7B 
G857A (rs1799931)
C282T (rs1041983) 
G286E 
Y94Y 
Slow 
    
NAT2*12A A803G (rs1208) K268R Rapid 
    
NAT2*12B 
A803G (rs1208) 
C282T (rs1041983) 
K268R 
Y94Y 
Rapid 
    
NAT2*12C 
A803G (rs1208) 
C481T (rs1799929) 
K268R 
L161L 
Rapid 
    
NAT2*13A C282T (rs1041983) Y94Y Rapid 
    
NAT2*14A G191A (rs1801279) R64Q Slow 
    
NAT2*14B 
G191A (rs1801279) 
C282T (rs1041983) 
R64Q 
Y94Y 
Slow 
Common non-synonymous nucleotide and amino-acid change are bolded.  
*Substrate dependent.  
Table 1. Common studied NAT2 haplotypes and associated acetylator phenotype. 
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Fig. 4. Haplotype classification is depend on gametic phase and may induce equivocally 
phenotype. Subject can be either rapid (A) or slow (B) acetylator depending on whether 
these mutations are located in the same or different chromosome.  
As current routine genotyping and sequencing methods typically provide unordered allele 
pairs for each marker, NAT2 haplotypes must be determined by inferring the phase of the 
alleles in order to assign an acetylator phenotype to a particular individual. Haplotype 
Phase Inference is based on transfer of ordered genotypes to all members in the pedigree at 
all loci, consistent with all observed genotype data and Mendelian segregation (readers may 
refer to an article by Slatkin 2008 for more details). In this regard, statistical and 
computational methods for haplotype construction from genotype data of random 
individuals received considerable attention due to several approaches have been developed 
to infer the true haplotype phase (Stephens & Donnelly 2003; Scheet & Stephens 2006). For 
example, there is a web server that implements a supervised pattern recognition approach 
to infer NAT2 acetylator phenotype (slow, intermediate or rapid) directly from the observed 
combinations of 6 NAT2 SNPs (Kuznetsov et al. 2009). Although haplotype data may also be 
obtained in family studies and experimentally from general population, these methods are 
considered laborious and expensive.  
4.3 From genetic alterations to protein function: Moving from pharmacogenetics to 
pharmacogenomics 
Given that genetic alteration may influence a protein function, several studies were 
conducted to assess how polymorphisms in genes of the corresponding DME can modify 
drug efficacy/toxicity and disease risk. In general, results have been obtained in 
epidemiologic or clinical studies and for better understanding of the population’s PGx. 
Consequently, in order to investigate these associations, both in vitro and in vivo studies 
using a variety of substrates have been performed to assign phenotypes to many identified 
genotypes. 
Functional studies and intracellular tracking of polymorphic variants are contributing to 
appreciation of how individual mutations modify protein function. In general, these studies 
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support the idea that different combinations of polymorphisms in the gene coding region 
result in proteins with altered stability, degradation, and/or kinetic characteristics. For 
example, slow acetylator NAT2 alleles showed reduced levels of NAT2 protein when 
compared with reference NAT2*4 allele, and possible mechanisms SNP-induced protein 
alteration are discussed elsewhere (Zang et al. 2007). Moreover, reductions in catalytic 
activity for the N-acetylation of sulfamethazine and 2-aminofluorene, a sulfonamide drug 
and an aromatic amine carcinogen respectively, were observed in NAT2 alleles possessing 
G191A, T341C, A434C, G590A, A845C or G857A (Fretland et al. 2001). As many chemicals 
cannot be tested in vivo, including certain human carcinogens, physiological effects of 
genetic alterations as SNPs and haplotypes, have been investigated in vitro in recombinant 
expression systems to determine the corresponding phenotypes. 
The effects of genetic alteration on proteins are the basis for bimodal or polymodal 
phenotypes. With these relations between genotype and phenotype recognized, studies 
have shown promising pathways supposed to be susceptibility molecular targets for a 
number of drug side effects and certain malignancies predisposed by DME genes 
polymorphisms. 
Furthermore, the molecular homology modeling techniques, including SNP locations and 
computational docking of substrates, have increased the understanding of the protein 
structure-function relationship. In this context, PGx has been a universal discipline 
providing many of the driving forces behind of the scientific development of the human 
genetics, pharmacology, clinical medicine and epidemiology. Additional evidences from 
laboratory-based experiments, haplotype mapping and clinical tests, lead us to believe that 
PGx will be a major contributor in the preventive and curative modern medicine. 
5. Clinical pharmacogenetics and potential applications 
Individual variability in plasma drug levels has been considered by many studies as a 
primary cause of therapeutic inefficacy and pharmacologic toxicity. Thus, matching patients 
to the drugs and dose that are most likely to be effective (maximizing drug efficacy) and 
least likely to cause harm (enhancing drug safety) is the main purpose of the novel 
contributions PGx. 
Clinically relevant examples of inherited variation that may influence the individual's drug-
metabolizing capacity and consequently pharmacokinetic properties of a drug are available in 
the literature. One of the earliest pharmacogenetic tests resulting in clinically important side 
effects was on the enzyme thiopurine methyltransferase (TPMT) (Krynetski et al. 1996). 
TPMT metabolizes two thiopurine drugs: azathioprine (AZA) and its metabolite 6-
mercaptopurine (6-MP), used in the treatment of autoimmune diseases and acute 
lymphoblastic leukemia. Polymorphism in TPMT gene causes some individuals to be 
particularly deficient in TPMT activity, and then thiopurine metabolism must proceed by 
other pathways, one of which leads to cytotoxic 6-thioguanine nucleotide analogues. This 
metabolite can lead to bone marrow toxicity and myelosuppression. Such genetic variation in 
TPMT affects a small proportion of people (approximately 0.3% of the population), though 
seriously. As empiric dose-adjustments of AZA and 6-MP is risky, TPMT genotyping before 
institution pharmacotherapy by identifying individuals with low or absent TPMT enzyme 
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activity may provide useful tools for optimizing therapeutic response and prevent toxicity 
(myelosuppression) (Krynetski & Evans 2003). In addition, TPMT genotype and drug 
adjustment may reduce the risk of secondary malignancies, including brain tumors and acute 
myelogenous leukemia (McLeod et al. 2000; Stanulla et al. 2005). 
NAT2 pharmacogenetics has attracted significant attention as N-acetylation polymorphism 
seems to predispose to an increased risk of drug-induced hepatotoxicity in patients 
administered isoniazid for the treatment of tuberculosis. Although exact mechanism of 
isoniazid-induced hepatotoxicity is unknown, recent studies have provided exciting results. 
Until recently, findings have proposed that metabolite responsible for isoniazid-induced 
hepatotoxicity was acetylhydrazine (AcHZ) which can undergo further metabolism by CYPs 
to toxic reactive acetyl free radicals in patients with slow NAT2 acetylation capacities (figure 
5). These toxic metabolites can form covalent bonds with liver cell macromolecules, interfering 
with their function and hepatocellular necrosis. In addition to this reason, some studies have 
also suggested that patients carrying both slow acetylator NAT2 and fast CYP2E1 isoforms 
may have a severe exacerbation outcome. Furthermore, it is believed that hydrazine (Hz) is 
also responsible for the isoniazid-induced hepatotoxicity based on results that metabolic 
activation of Hz causes hepatic disorder. Also in this second proposition, slow acetylators may 
be injured since Hz is metabolized by NAT2 to the less toxic derivative diacetylhydrazine 
(DiAcHZ), which is then excreted in the urine. On the other hand, fast acetylation of AcHZ 
and Hz in NAT2 rapid acetylators should theoretically form DiAcHZ efficiently and therefore 
reducing the oxidative metabolites accumulation from AcHZ. In fact, several studies found an 
increased risk in slow versus fast acetylators through genetically determined phenotype 
(Higuchi et al. 2007). However, there are conflicting data on whether CYP2E1 genotypes do or 
do not increase the risk of isoniazid-induced (Cho et al. 2007). 
 
Fig. 5. Major enzymes involved in isoniazid biotransformation and relevant metabolites.  
Isoniazid metabolic pathways clearly exemplify that elimination of most drugs involves the 
participation of several families of drug metabolizing enzymes. Therefore, it is incoherent 
thought that one or few isolated host factors that only response to drugs. However, there are 
few studies focusing on the relationship between the genotypes of related enzymes and 
susceptibility to drug adverse reactions. As shown in Figure 5, is theoretically possible that 
GST isoforms, which are genetically determined to a great extent, may also influence INH 
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metabolism. In this way, a study found that well known GSTM1 null genotype influenced 
the serum concentration of Hz in the NAT2 slow acetylators independently of their CYP2E1 
phenotype (Fukino et al. 2008). Thus, more efforts are necessary to uncover the important 
question: interactions between NAT2 and CYP2E1 phenotypes, in addition to the GSTs, may 
have potential risks for isoniazid-induced hepatotoxicity? Thus, as a general rule, a better 
understanding of genetic factors in a more studies manner will be useful to demonstrate that 
prediction of toxicity is possible and consistently reliable. 
In addition to significant number of publications available in the scientific literature, others 
comprehensive, public online resources are also available for beginners and experts in PGx. 
Undoubtedly, one of the most important is Pharmacogenomics Knowledge Base 
(PharmGKB, http://www.pharmgkb.org). The reader will find up-to-date information 
about the most important genes involved in drug response, highlighted summaries, 
pathway diagrams, and accurate literature (Sangkuhl et al. 2008). In general, the ultimate 
goal of such services is to guide appropriate PGx knowledge. Common data collected (with 
few modifications) from PharmGKB in regard to PGx polymorphisms of phase I DMEs and 
clinical associations are summarized in Table 2. Since we discussed earlier about PGx of 
CYP2D6, we purposely excluded it this table. 
 
Gene Common 
Alleles/Effect 
Common 
substrates 
Clinical 
evidences 
References 
 
CYP2A6 
 
*2 (L160H) 
*5 (G479V) 
*7 (I471T) 
*11 (S224P) 
*12 (10 aa 
substitutions) 
*17 (V365M) 
*18 (Y392F) 
*20 (196 frameshift) 
 
Coumarin,  
SM-12502,  
Tegafur#,  
Nicotine and  
5-Fluorouracil 
 
Influence on 
nicotine adverse 
effects and 
variability in quit 
smoking 
 
(Malaiyandi et 
al. 2006; Ozaki 
et al. 2006; Ho et 
al. 2008)   
  Altered 
therapeutic 
responses to 
antineoplastic 
Tegafur 
(Daigo et al. 
2002; Kong et al. 
2009)  
CYP2B6 *2 (R22C) 
*4 (K262R) 
*5 (R487C) 
*6 (Q172H; K262R) 
 
Tamoxifen, Clopidogrel#, 
Carbamazepine#, 
Cyclophosphamide, 
Nicotine and Diazepan 
Efavirenz effect 
and central 
nervous system 
side effects 
(Haas et al. 
2004; Ribaudo et 
al. 2010)  
   Sub-therapeutic 
plasma 
concentrations of 
efavirenz 
(Rodriguez-
Novoa et al. 
2005; ter Heine 
et al. 2008) 
   Benefits of 
efavirenz dose 
adjustment 
(Gatanaga et al. 
2007; ter Heine 
et al. 2008) 
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Gene Common 
Alleles/Effect 
Common 
substrates 
Clinical 
evidences 
References 
 
CYP2C9 
 
*2 (R144C) 
*3 (I359L) 
*5 (D360E) 
*6 (273 frameshift) 
*13 (L90P) 
Warfarin, Phenytoin, 
Tolbutamide, 
Glibenclamide, Gliclazide, 
Fluvastatin, Losartan,  
Ritonavir and Tipranavir. 
Variability in 
warfarin therapy 
and elevated risk 
of severe 
bleeding 
 
(Aithal et al. 
1999; Takahashi 
et al. 2006; Gan 
et al. 2011)  
  Elevated risk of 
hypoglycemia 
attacks during 
oral antidiabetic 
treatment. 
(Kidd et al. 
1999; Tan et al. 
2010; Gokalp et 
al. 2011)  
 
  More frequent 
symptoms of 
overdose in 
phenytoin 
therapy 
(Ninomiya et al. 
2000; van der 
Weide et al. 
2001; Kesavan et 
al. 2010)  
 
CYP2C19 *2A (splic; I331V) 
*2B (splic; E92D) 
*2C (splic; A161P; 
I331V) 
*3A (W212X; I331V) 
*3B (W212X; D360N; 
I331V) 
*9 (R144H; I331V) 
*17 (I331V) 
Mephenytoin, 
Lansoprazole, 
Omeprazole, Selegiline,  
Imipramine, 
Fluoxetine 
Diazepan, 
Phenobarbital and 
Proguanil 
Inadequate 
response to 
clopidogrel* and 
higher rate of 
major adverse 
cardiovascular 
events 
(thrombosis) 
 
(Mega et al. 
2009; Mega et al. 
2010; Kelly et al. 
2011)  
   Increased risk of 
proguanil 
treatment 
failures 
 
(Kaneko et al. 
1997) 
   Differences in 
clinical efficacy 
of proton pump 
inhibitors. 
(Zhao et al. 
2008; Furuta et 
al. 2009; Sheng 
et al. 2010; Yang 
& Lin 2010)  
 
   Nelfinavir 
pharmacokinetics 
and virologic 
response in HIV-
1-infection. 
(Saitoh et al. 
2010) 
#prodrugs;  aa: amino acid; splic: splicing defect. More information about allele, protein, nucleotide 
changes, trivial name and effect of the gene of polymorphism on enzyme activity may be found in  
http://www.cypalleles.ki.se/index.htm and http://www.snpedia.com/index.php/SNPedia. 
 
Table 2. Common alleles, substrates and clinical evidences of some CYPs. 
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6. Ethnic characterization is not sufficient to reach pharmacogenetic goals: 
Focus on personal genomics 
Inherited determinants generally remain stable throughout a person’s lifetime (unlike other 
factors influencing drug response), making the pharmacogenetics approach attractive. 
However, both interethnic and intraethnic variability for a specific allele in human 
populations are extremely large and may have relevant clinical implications. NAT2 is a good 
example of such gene. Several NAT2 SNPs causing defective enzymes are heterogeneity 
distributed in the world making 50% of Caucasians but only 10% of Japanese slow 
acetylators, for example. Moreover, our research group demonstrated that some 
discrepancies in allelic frequencies in an important DME, even within the same population. 
(Magno et al. 2009).  
Undoubtedly, PGx variability explains in part why there are important differences in 
response to conventional drug-based therapies among different ethnic groups. But, from a 
biological standpoint, what are the probability to predict efficiently and accurately an 
individual response to drug from a multi-ethnic study? Low, at least. Several evidences 
have provided enough data to concern about it. Attempts to predict genotypes and 
phenotypes from ethnic perspectives have been become less meaningful, mainly in parts of 
the world in which people from different regions have mixed extensively. Thus, recent 
studies have pointed out that ethnicity not always serves as a start point to define drug 
regimes because it typically not emphasizes biological components. To group individuals in 
only a same category based in non-biological criteria, is to assume that people from these 
groups have same biological backgrounds. For example, clinical and pharmacological trials 
have traditionally considered the different geographical regions of Brazil as being very 
heterogeneous. However, a recent study found that the genomic ancestry of subjects from 
these different regions of Brazil is more homogeneous than anticipated (Pena et al. 2011). In 
the same way, individual categorization depends not on physical appearance of the subjects 
(Parra et al. 2003).  
Therefore, it is evident that results from population studies could be useful in some 
situations, but the fact that subjects have their own variations reinforce the necessity to 
study an individual's genetic profile and not ethnic populations.  
7. Are PGx approaches cost-effective?  
Unquestionably, some success has been achieved in recent years in establishing the clinical 
utility of the pharmacogenetic testing. However, it remains questionable whether it is cost-
effective or not. To justify routine testing, PGx technology must be more practical than the 
available approaches and involve a clinical benefit higher than those reported and 
sufficiently to cover expenditures in genetic testing. Unfortunately, data on cost-
effectiveness of PGx are currently limited and have been the subject of controversy in the 
literature. A possible explanation is that therapeutic outcomes depend on many poorly 
defined factors other than pharmacogenetic variation, such as the cost of therapeutic failure 
and circumstances surrounding patient therapy. Furthermore, to address the issue of 
“effectiveness” is difficult, considering that PGx purposes not only attempt save time and 
money, but also avoids any unnecessary physical suffering and emotional traumas.  
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In general, studies have shown that PGx is potentially cost-effective under certain 
circumstances (Carlson et al. 2009; Vegter et al. 2009; Meckley et al. 2010). Some authors 
consider that findings showing non-robust benefit of PGx testing are due to limited 
knowledge of its therapeutic application since access to technology and genotyping 
expenses are no longer limiting factors. Influence of CYP2D6 alleles on therapeutic efficacy 
of psychiatry drugs clearly illustrates this. Besides the influence of CYP2D6 alleles on 
metabolism of most antipsychotics drugs, studies investigating the association between 
CYP2D6 genotypes and antipsychotic response have reported no predicted clinical 
improvement (Zhang & Malhotra 2011). Probably, this enzyme only has a significant clinical 
impact on a smaller non-investigated subgroup of drugs. In fact, a genetic variation that 
merely affects the drug elimination, modestly increase the frequency of an adverse effect or 
a common side effect that is well tolerated may still not be of sufficient importance to justify 
pharmacogenetic testing.  
Presumably, cost-effectiveness of PGx also can vary from high to low depending on the 
illness and gene involved. According to this proposition, important support of the cost-
effectiveness of PGx comes from clinical situations where PGx variations have major impact 
on therapeutic outcomes and clinical cost. Genotyping of TPMT before starting azathioprine 
treatment (Hagaman et al. 2010), HTR2A (serotonin 2A receptor) in selective serotonin 
reuptake inhibitors therapy (Perlis et al. 2009) and CYP2C9 plus VKORC1 (vitamin K 
epoxide reductase complex subunit 1) before warfarin treatment (Leey et al. 2009; You 2011) 
are well-known examples.  
Important to date that economic evaluations of PGx have all highlighted the need to 
improve the quality of the evidence-based economics (Payne & Shabaruddin 2010), since a 
number of studies have been inconclusive (Verhoef et al. 2010). Finally, it is possible that the 
rapidly decreasing cost of genetic analysis and knowledge of the therapeutic application of 
PGx will be able systematically to make PGx approaches more and more cost-effective 
technology. 
8. Ethics in PGx and final considerations 
Past lessons had enabled us to see the rising of personalized prescriptions in improving  
prevention of serious adverse drug reactions, therapeutic effect and patient compliance. 
However, they have not resolved the ethical issues that are emerging in PGx 
research. Although the barriers between technological advances and the view of human 
well-being are not so clear-cut, both perspectives will be discussed below. 
The first issue comes from the source of PGx data: human samples. Samples and data 
collected as a part of the research are stored and offer robust information about genome, 
cells, biological functions, life-style, previous diseases, and many others. Although it seems 
like a conspirator theory or just an ideological issue, because historical facts unfortunately 
have failed to clearly show this fact. A businessman from Seattle called John Moore 
developed hairy cell leukemia and was treated by a highly qualified team from a notorious 
research center of an American University. Then, Moore returned to the center in order 
monitor his condition seven years later, fearing a recurrence of the leukaemia. However, he 
was shocked to learn that besides his physician’s preoccupation about his health, there 
indeed was another interest at stake. And that was a million dollar contract that was already 
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negotiated and signed, to develop a cell line from Moore blood sample (now known as “Mo-
cell line”) without Moore’s consent. It became a court case. Surprisingly, California Supreme 
Court decided the case in favour of the physician. This landline decision gave a clear 
impetus to commercialization of samples from human and led to patents developed from 
human samples. After that, new patents based on human samples gave a new gold rush 
treasure. It is obvious that the chapter’s purpose is not to go deeper in this kind 
of philosophical issues, but the reader must think about the real impact of what the 
informed consent really represent and what should guide its free applications. Moreover, 
many studies involving thousands of individuals with application of "reconsents" and 
"tiered consent" aiming to obtain specimens to future research will also new clinical 
directives in PGx research. 
A second bioethical hallmark allow the subject or patient confidentiality. How, for whom 
and why will the information be accessed? As a part of clinical diagnosis, it seems more 
reasonable that the patients themselves have special interest and the confidentiality is not 
different as in the case of other diseases. However, could patients’ relatives know about 
inherited disorders or increased disease risk? Could employers and health insurances 
companies have access to this genetic information? For instance, we may suppose a 
company looking for employees based on the “tolerance levels” to exposure of occupational 
toxicants. In this regard, studies have shown a wide range of carcinogenic toxicants such as 
arsenic (Hernandez et al. 2008; Paiva et al. 2010), benzene (Sapienza et al. 2007) and 
polycyclic aromatic hydrocarbons (Rihs et al. 2005) in which detoxification is genetically 
influenced. Thus, should this information be used for admission or even resignation? 
Defenders of the breaking of genomic confidentiality usually have highlighted the cost-
benefit of “protecting his/her own health”, but some health insurance companies may use 
these data to introduce different fares depending on individual susceptibility such as “high 
costs” for subjects defined as “higher disease risk”, for example. Actually there is no novelty 
on that since many worldwide apply different rates for automobiles or health insurance 
based on age, gender, life-style, previous disease and some others. In fact, companies, 
regulatory and public funding agencies are discussing how to integrate PGx practice into 
public health care (Robertson et al. 2002; Evans 2010).  
Examples above illustrated lead to a third reflection: Equity. As discussed by Peterson-Iyer, 
“market forces do not guarantee justice in the distribution of health care”. In a different way of 
the "one-size-fits-all" (a blind approach for drug prescription with regard to their 
pharmacokinetic profile), PGx approaches improving drug safety and efficacy are already 
beginning to be performed only in some private and medical centers. It is unquestionable that 
in short time clinical practice of PGx will favor highly sophisticated higher one’s economic 
status. If currently there are a significant numbers of subjects uninsured for basic health care, 
would PGx rectify or exacerbate the profoundly disturbing those with higher economic status 
inequalities in the health care system? (Peterson-Iyer 2008). Indeed many other bioethical 
questions might be relevant, which we may not be able to treat here. We encourage the readers 
to read further on this subject from various excellent articles on these issues (Williams-Jones & 
Corrigan 2003; Weijer & Miller 2004; Patowary 2005; Sillon et al. 2008; Howard et al. 2011). 
In conclusion, unequivocally DMEs still remain helping to elucidate the well-known 
mechanisms of variability in drug response and have been the major contributor in the 
successful advances in PGx (Freund et al. 2004; Jaquenoud Sirot et al. 2006; Swierkot & 
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Slezak 2011). Past lessons have taught us to consider each individual as a unique person 
from metabolic perspective. Currently, PGx is leading us to uncover several and potential 
applications of PGx in the clinical practice, which involves an interconnected puzzle pieces 
with patients, health professionals, industry and governmental regulatory agencies. Finally, 
PGx starts to tell us that all its benefits should also be applied in a close future for all 
members of the society and though differences in our DNA, pharmacogeneticians always 
worked together in the same perspective to improve the health of people without 
distinction.   
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